Skip to main content

Adicet Bio, Inc. (ACET)

NASDAQ: ACET · IEX Real-Time Price · USD
7.60 0.32 (4.40%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap242.00M
Revenue (ttm)9.27M
Net Income (ttm)-55.91M
Shares Out31.82M
EPS (ttm)-2.70
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume170,597
Open7.32
Previous Close7.28
Day's Range7.25 - 7.89
52-Week Range6.25 - 17.80
Betan/a
AnalystsStrong Buy
Price Target28.29 (+272.2%)
Est. Earnings DateNov 4, 2021

About ACET

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company a...

IndustryHealth Care Providers & Services
Founded1947
CEOChen Schor
Employees81
Stock ExchangeNASDAQ
Ticker SymbolACET
Full Company Profile

Financial Performance

In 2020, Adicet Bio's revenue was $17.90 million, an increase of 1,699.30% compared to the previous year's $995,000. Losses were -$36.68 million, 30.4% more than in 2019.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for Adicet Bio stock is "Strong Buy." The 12-month stock price forecast is 28.29, which is an increase of 272.24% from the latest price.

Price Target
$28.29
(272.24% upside)
Analyst Consensus: Strong Buy

News

Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif. & MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience and Adicet Bio collaboration to accelerate the discovery of gamma delta T cell therapies against five undiscl...

Other symbols:TWST
1 week ago - Business Wire

Adicet Bio to Participate in Upcoming Investor Conferences

MENLO PARK, Calif. and BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer a...

3 weeks ago - GlobeNewsWire

Adicet Bio, Inc. (ACET) Reports Q2 Loss, Tops Revenue Estimates

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 33.33% and 6.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Adicet Reports Second Quarter 2021 Financial Results and Provides Business Updates

On track to report top-line interim data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by the end of 2021 On track to report top-line interim data from ADI-001 Phase 1 study in Non-Hodgkin'...

1 month ago - GlobeNewsWire

Adicet Bio to Participate in Upcoming Investor Conferences

MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other dis...

1 month ago - GlobeNewsWire

Adicet Bio Announces Formation of Scientific Advisory Board

MENLO PARK, Calif and BOSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and...

2 months ago - GlobeNewsWire

Adicet Bio Added to the Russell 2000® Index

MENLO PARK, Calif. and BOSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer an...

2 months ago - GlobeNewsWire

Moving Average Crossover Alert: Adicet Bio (ACET)

Adicet Bio (ACET) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

3 months ago - Zacks Investment Research

New Strong Sell Stocks for May 28th

ACET, FURY, KRYS, MRSN, and NBEV have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2021

Other symbols:FURYKRYSMRSNNBEV
3 months ago - Zacks Investment Research

Adicet Bio to Participate in Upcoming Investor Conferences

MENLO PARK, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other dise...

4 months ago - GlobeNewsWire

Adicet Reports First Quarter 2021 Financial Results and Provides Business Updates

MENLO PARK, Calif. and BOSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies...

4 months ago - GlobeNewsWire

Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research

MENLO PARK, Calif. and BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer a...

5 months ago - GlobeNewsWire

Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

MENLO PARK, Calif. and BOSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer a...

6 months ago - GlobeNewsWire

Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors

MENLO PARK, Calif. and BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer a...

6 months ago - GlobeNewsWire

Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private Placement and Exercise in F...

MENLO PARK, Calif. and BOSTON, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell thera...

7 months ago - GlobeNewsWire

Adicet Bio, Inc. Announces Pricing of $135 Million Public Offering of Common Stock and Concurrent Private Placement

MENLO PARK, Calif. and BOSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies fo...

7 months ago - GlobeNewsWire

Adicet Bio, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

MENLO PARK, Calif. and BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies fo...

7 months ago - GlobeNewsWire

Adicet: Promising 2021 Therapeutic Initiations, Cash Of $108 Million, And New Management

Adicet Bio is a biotechnology company concentrated on developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a pre-clinical pipeline of 4 therapeutics cov...

8 months ago - Seeking Alpha

Adicet Bio (ACET) Surges: Stock Moves 5.9% Higher

Adicet Bio (ACET) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit

MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cance...

9 months ago - GlobeNewsWire

Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors

MENLO PARK, Calif. and BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...

9 months ago - GlobeNewsWire

Adicet Reports Third Quarter 2020 Financial Results and Provides Business Update

MENLO PARK, Calif. and BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...

10 months ago - GlobeNewsWire

Adicet Appoints Don Healey, Ph.D., as Chief Technology Officer

MENLO PARK, Calif. and BOSTON, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...

10 months ago - GlobeNewsWire

Adicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy

Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin's lymphoma Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell n...

11 months ago - GlobeNewsWire